Efficacy of divozilimab in the treatment of systemic sclerosis: results of the randomized phase III clinical trial BCD-132-5/LIBERIUS

Bibliographic Details
Title: Efficacy of divozilimab in the treatment of systemic sclerosis: results of the randomized phase III clinical trial BCD-132-5/LIBERIUS
Authors: L. P. Ananyeva, M. N. Starovoytova, I. Z. Gaydukova, G. V. Lukina, E. V. Zonova, L. V. Eliseeva, G. F. Fatkhullina, D. I. Abdulganieva, D. G. Krechikova, T. V. Kropotina, O. B. Nesmeyanova, I. B. Vinogradova, E. S. Zhugrova, L. V. Ivanova, N. E. Nikulenkova, O. R. Ziganshin, T. V. Plaksina, M. V. Zlobin, Yu. Yu. Grabovetskaya, N. F. Soroka, O. B. Ershova, T. V. Povarova, O. N. Anoshenkova, A. A. Lutsky, A. V. Zinkina-Orikhan, Yu. N. Linkova, E. A. Fokina, A. A. Porozova, A. V. Eremeeva
Source: Современная ревматология, Vol 19, Iss 1, Pp 44-48 (2025)
Publisher Information: IMA-PRESS LLC, 2025.
Publication Year: 2025
Collection: LCC:Medicine
Subject Terms: divozilimab, systemic sclerosis, systemic scleroderma, Medicine
More Details: The search for new therapeutic options for the treatment of systemic sclerosis (SSc) is an urgent issue in rheumatology. The article presents the results of the double-blind, randomized, placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS on the efficacy and safety of divozilimab (BCD-132) in the treatment of SSc.Objective: to investigate the efficacy and safety of divozilimab in patients with SSc compared to placebo.Material and methods. After enrolment in the study, patients received divozilimab or placebo for 48 weeks, after which they were switched to an open-label divozilimab therapy until week 96.Results and discussion. Divozilimab was superior to placebo regarding the primary endpoint change in mRSS at week 48 compared to baseline, and the therapy had a positive effect on respiratory function parameters. Divozilimab treatment was well tolerated.Conclusion. Thus, divosilimab may represent a new therapeutic option for patients with SSc.
Document Type: article
File Description: electronic resource
Language: Russian
ISSN: 1996-7012
2310-158X
Relation: https://mrj.ima-press.net/mrj/article/view/1700; https://doaj.org/toc/1996-7012; https://doaj.org/toc/2310-158X
DOI: 10.14412/1996-7012-2025-1-44-48
Access URL: https://doaj.org/article/a2ae60f641cf4b81abfd00e2c0f51740
Accession Number: edsdoj.2ae60f641cf4b81abfd00e2c0f51740
Database: Directory of Open Access Journals
More Details
ISSN:19967012
2310158X
DOI:10.14412/1996-7012-2025-1-44-48
Published in:Современная ревматология
Language:Russian